Home / Conditions / Hallux Rigidus
Hallux Rigidus: when insurers say no, reviewers often say yes
In 19 published external-review decisions involving hallux rigidus, independent physician reviewers overturned the insurer’s denial 63.2% of the time.
Published decisions
19
2001–2026
Overturned
63.2%
12 denials reversed
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 12 | 58.3% |
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 7 | 71.4% |
Typical time to a decision
20 days
Most land between 10 and 22 days
Handled as urgent
15.8%
Expedited when a delay would cause harm
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for left foot hallux rigidus correction surgery (first metatarsophalangeal hemiarthroplasty utilizing Cartiva implant and dorsal cheilectomy). Current studies and literature comparing the use of the Cartiva implant to arthrodesis of the first MTP joint to treat hallux rigidus have mixed results in identifying a superior procedure. Most noted that additional studies with larger cohorts and longer follow-ups are needed to further access the ideal treatment. The records indicate that this patient was experiencing pain in the left first MTP joint which made walking and running painful. In addition, the patient’s job requires walking for most of the day. Per the provider, conservative treatment did not provide substantial pain relief.
Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for a hemi-titanium implant inserted during the hallux rigidus repair surgery of the right great toe. Treatment options for patients with hallux rigidus include both conservative modalities and operative procedures. Conservative treatments include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroid injections, physical therapy, and footwear modifications. Surgical alternatives include arthrodesis, Keller arthroplasty, arthrodiastasis, cheilectomy, and hemiarthroplasty with implant placement. The current medical literature suggests that more favorable outcomes are noted with hemiarthroplasty of the first metatarsophalangeal joint (MPJ) as compared to arthrodesis.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for first metatarsophalangeal joint (MPJ) cheilectomy, debridement and capsular release with Cartiva implant of the left foot. Based on the records provided for review, this patient underwent first MPJ cheilectomy with Cartiva implant of the left foot for hallux rigidus of the left first MPJ. The Cartiva implant is a synthetic implant placed within the first MPJ to treat osteoarthritis and hallux limitus. Current medical literature suggests that additional studies are needed to determine whether the Cartiva implant can provide superior health outcomes when compared to standard of care approaches such as arthrodesis of the first MPJ. Long-term data have demonstrated the safety and efficacy of arthrodesis with excellent and reproducible results.
An enrollee has requested reimbursement for the Cartiva implant procedure. The records provided for review document painful left-sided hallux rigidus and hallux valgus. From a surgical perspective, first metatarsophalangeal joint arthrodesis or first metatarsophalangeal joint metallic implant remain the longstanding surgical standards of care for hallux rigidus. Numerous studies have demonstrated that well-selected patients can benefit with first metatarsophalangeal joint arthrodesis and are able to continue with vigorous physical activity. Metallic implants for the base of the proximal phalanx and the head of the first metatarsal have been shown to be safe and effective for the treatment of painful hallux rigidus. The Cartiva implant is a novel first metatarsophalangeal joint implant.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
How to use this in your appeal
These outcomes come from California’s external review program — an independent physician panel whose decision binds the insurer. Every state has an equivalent, and internal appeals succeed even more often. If your care for hallux rigidus was denied, the published record says the denial is worth fighting.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.